We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Premaitha | LSE:NIPT | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.10 | 9.00 | 9.20 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
01/10/2016 12:42 | Point is Twix... the bullies ain't gonna win..!! it won't even get near a court. | hjb1 | |
30/9/2016 19:12 | But its quite clear that they are backed in the legal dispute by Thermo and by Roche and by the EU. The EU can fine them a multiple of their annual turnover! None of these actions have previously made it to court and I doubt Illumina will want to risk going to court. If they lost not only could they face EU fines but would lose their market. Much better to settle. My understanding is that, particularly in relation to the EU, but probably in court, they could not just shut down Premaitha but would have to offer them 'commercial' terms, i.e. similar terms to what they have done licence deals for, which would be a relatively smalll fee. The massive markdown by the market is not justified by the possible outcomes, even the worst case would not be terminal. | 62rick | |
30/9/2016 18:54 | FSE Its the litigation aspect that moved these out of the 20p range...and the 30p, quite why hj finds that hilarious is baffling. | blackss | |
30/9/2016 18:48 | Results were IMO very solid with plenty of growth possibilities ahead. If it was not for the dark shadow of the litigation hanging over them these would have really motored on these results. Surprised even with the litigation aspect that they have not moved up into the 20p range..... | fse | |
30/9/2016 18:31 | "At least they are borrowing money rather than diluting but that's about as good as it gets i think till they go to court".... ha ha hilarious!! | hjb1 | |
30/9/2016 17:14 | Premaitha have never been first on the market and for your information the company you refer to have over 600k tests completed | dave444 | |
30/9/2016 16:48 | At least they are borrowing money rather than diluting but that's about as good as it gets i think till they go to court.... | blackss | |
30/9/2016 13:44 | I've had some, powerful growth, recession proof. Not priced in. | hurricane. | |
30/9/2016 12:58 | cup formation @ 20p, to breakout.....by Xmas | deanroberthunt | |
30/9/2016 11:08 | "The next phase of Premaitha's growth strategy should see significant expansion opportunities within the Far-East over the next twelve months and I look forward to updating shareholders shortly on our progress" news coming very soon it seems!. | brainspark1 | |
30/9/2016 11:08 | Commercial opportunities We finished the 2015/16 financial year strongly and have seen this momentum continue into the current financial year. We are seeing continued growth in our installed base within Europe and what is very encouraging is the growth and momentum we are experiencing for IONA(R) within the Middle East and Asia. I believe during the course of the next twelve months these territories will become very dominant for us in terms of revenue growth and where we do not face the same litigation issues as in Europe. We have built an extremely robust business with substantial global opportunities, I am very proud of what we have achieved and becoming a global business. Although the short to medium term focus will be partially centered on the litigation and its distractions, one must not forget the progress we have made and the substantial growth opportunities we have ahead of us. | brainspark1 | |
30/9/2016 09:40 | If revenue was £2.5M with 4 operational labs towards the back end of last FY, with 9 operational now, that must mean they have revenue of £5m for H1 this FY ! | brainspark1 | |
30/9/2016 09:37 | " Product registrations commenced in Mexico and Canada " Looks like we are going to USA's backyard lol | brainspark1 | |
30/9/2016 09:24 | heading back to 20p imho. off topic take a look at ENGI. I posted some info on the bb. | cliley454 | |
30/9/2016 09:11 | Was always going to happen...Plenty of labs to go around, and Premaitha have the best resellers/distributo See Genoma sales growth...170% per half year | brainspark1 | |
30/9/2016 09:07 | Anyone have a view on the significance of the Roche CE mark news? | philburt | |
30/9/2016 08:47 | this'll intraday reverse today, punters already paying over stated offer 10.69999 | deanroberthunt | |
30/9/2016 08:46 | already started to turn up.... | deanroberthunt | |
30/9/2016 08:45 | chart looks a peach aswell to start the righthand side of the cup/bowl | deanroberthunt | |
30/9/2016 08:42 | Also any NHS decision is imminent | brainspark1 | |
30/9/2016 08:40 | has a feel of Alliance Pharma about it.... | deanroberthunt | |
30/9/2016 08:36 | win the case it'll be 20p in a flash just for starters | deanroberthunt | |
30/9/2016 08:31 | in with 100k just for starters... | deanroberthunt | |
30/9/2016 08:30 | No ramping, just impressive growth to 13 labs by end of 2016. Being using this dip to my advantage | brainspark1 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions